Andy Plump, Takeda R&D chief (Jeff Rumans for Endpoints News)
What kind of PhIIb data is worth $4B cash? Takeda’s Andy Plump has some thoughts on that
A few months back, when Takeda caused jaws to drop with its eye-watering $4 billion cash upfront for a mid-stage TYK2 drug from Nimbus, it …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
